213 related articles for article (PubMed ID: 9676842)
1. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
Kramer EL; Liebes L; Wasserheit C; Noz ME; Blank EW; Zabalegui A; Melamed J; Furmanski P; Peterson JA; Ceriani RL
Clin Cancer Res; 1998 Jul; 4(7):1679-88. PubMed ID: 9676842
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
DeNardo SJ; Kramer EL; O'Donnell RT; Richman CM; Salako QA; Shen S; Noz M; Glenn SD; Ceriani RL; DeNardo GL
J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145
[TBL] [Abstract][Full Text] [Related]
3. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
4. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.
Kramer EL; DeNardo SJ; Liebes L; Kroger LA; Noz ME; Mizrachi H; Salako QA; Furmanski P; Glenn SD; DeNardo GL
J Nucl Med; 1993 Jul; 34(7):1067-74. PubMed ID: 8315480
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
10. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
12. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
13. Biokinetics of yttrium-90--labeled huBrE-3 monoclonal antibody.
Johnson TK; Cole W; Quaife RA; Lear JL; Ceriani RL; Jones RB; Cagnoni PJ
Cancer; 2002 Feb; 94(4 Suppl):1240-8. PubMed ID: 11877752
[TBL] [Abstract][Full Text] [Related]
14. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
16. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
17. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.
Leichner PK; Akabani G; Colcher D; Harrison KA; Hawkins WG; Eckblade M; Baranowska-Kortylewicz J; Augustine SC; Wisecarver J; Tempero MA
J Nucl Med; 1997 Apr; 38(4):512-6. PubMed ID: 9098192
[TBL] [Abstract][Full Text] [Related]
18. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.
Schrier DM; Stemmer SM; Johnson T; Kasliwal R; Lear J; Matthes S; Taffs S; Dufton C; Glenn SD; Butchko G
Cancer Res; 1995 Dec; 55(23 Suppl):5921s-5924s. PubMed ID: 7493371
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
20. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
DeNardo SJ; DeNardo GL; Yuan A; Richman CM; O'Donnell RT; Lara PN; Kukis DL; Natarajan A; Lamborn KR; Jacobs F; Siantar CL
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
